Thirteen healthcare funds — including Perceptive, Cormorant, and Foresite — simultaneously backed the same inhaled rapamycin program, a degree of syndicate convergence that signals genuine conviction rather than passive FOMO allocation. Quince Therapeutics absorbed Orphai and its lead asset LAM-001 in a stock-for-stock deal, then immediately raised $115 million upfront through a Series C preferred PIPE, with warrants that could push total proceeds to $187 million. That runway extends through end-2028 and covers three sequential data readouts across distinct pulmonary indications.
The strategic logic is straightforward but the execution risk is real. LAM-001 is an inhaled formulation of sirolimus — a decades-old mTOR inhibitor whose systemic toxicity profile has long constrained its utility. The inhaled delivery is the entire bet: localize the drug in the lung, suppress vascular smooth muscle proliferation and fibroblast activation, and sidestep the immunosuppression and metabolic side effects that made oral rapamycin a non-starter in chronic pulmonary disease. Phase 2a data presented at ATS were compelling enough to attract this syndicate, but Phase 2a data in rare pulmonary diseases have a well-documented history of failing to replicate. Quince is moving straight into a Phase 2b in PH-ILD with data expected Q1 2028 — no pause to run additional mechanistic work — which tells you the company believes the signal is durable, not just statistically decorative.
The multi-indication strategy is where Quince’s positioning becomes genuinely interesting. PH-ILD carries roughly 86,000 U.S. patients and no approved disease-modifying therapy. BOS post-lung-transplant is smaller but has essentially no pharmacological standard of care beyond intensified immunosuppression. SAPH is rarer still, with zero approved agents. Three underserved orphan populations, one delivery platform, and a mechanism with plausible biology across all three — that is the pitch to payers and acquirers alike. Running parallel Phase 2 programs in BOS and SAPH while executing a Phase 2b in PH-ILD is operationally aggressive on a $115 million upfront, but the staggered readout schedule — Q1 2027, Q1 2028, Q4 2028 — means each dataset can inform portfolio decisions before cash is fully deployed.
The single marker that will define this program’s trajectory is the BOS Phase 2 readout in Q1 2027: it arrives earliest, its patient population has clearly defined transplant-date baselines, and a clean signal there would validate the inhaled-mTOR hypothesis before the far larger and more expensive PH-ILD bet reaches its conclusion.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
